Maplirpacept

DB18441InvestigationalProtein Based Therapies

Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.

Mechanism: Maplirpacept binds to and blocks the human cell surface antigen CD47.
Curator reviewed · 2 references
Also known as: 1-118-Signal regulatory protein α (human) fusion protein with immunoglobulin G4 [128-proline] (human γ4-chain C region C-terminal fragment), dimer · SIRPA-IGG4-FC FUSION PROTEIN TTI-622
Code names: PF-07901801 · TTI-622

Resolves to

Compound

UNII44D51T6SZH

Targets

Q08722CD47

What you can answer from here — as of June 16, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Maplirpacept, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account